Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Eperisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.87 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.87 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.87 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.87 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.87 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.87 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eperisone SCHEMBL1331682 | 0.93 | HRH3 (1.00) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL194769 | 0.93 | HRH3 (1.00) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL218337 | 0.92 | HRH3 (0.97) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Inaperisone SCHEMBL250427 | 0.92 | HRH3 (0.97) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Inaperisone SCHEMBL3990438 | 0.91 | CHRM2 (0.94) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Inaperisone SCHEMBL1650087 | 0.89 | HRH3 (0.92) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL2491287 | 0.87 | HRH3 (0.87) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL2489151 | 0.86 | HRH3 (0.85) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL1331476 | 0.86 | HRH3 (0.85) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL1331479 | 0.86 | HRH3 (0.85) | HRH3CHRM2ADRA2BDRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196895-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110281911-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2379502-A2 | NOVEL FORMS OF EPERISONE | Bionevia Pharmaceuticals Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010081070-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010017135-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281911-A1 | NOVEL FORMS OF EPERISONE | PTGER1, PTGER2, PTGER3 | ADRA2B 588/4885DRD3 1451/4885ADRA2C 286/4885 |
| US-20120196895-A1 | NOVEL FORMS OF EPERISONE | PTGER1, MTPN, PTGER2 | ADRA2B 1262/4885DRD3 1605/4885ADRA2C 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.